November 9, 2006

VIA EDGAR AND FACSIMILE		Emergent BioSolutions, Inc. 300 Professional Drive, Suite 250 Gaithersburg, MD 20879
Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549		t 301 944 0290 f 301 944 0173 www.emergentbiosolutions.com

Attention: Song P. Brandon, Esq.

Re:		Emergent BioSolutions Inc.
		Registration Statement on Form S-1
		File No. 333-136622
		Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Emergent BioSolutions Inc., a Delaware corporation (the “Company”), hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-136622), as amended (the “Registration Statement”), so that it may become effective at 5:00 p.m. Eastern time on November 14, 2006, or as soon thereafter as practicable.

The Company hereby acknowledges that:

(i)		should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(ii)		the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
iii)		the Company may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

J.P. Morgan Securities Inc.
Cowen and Company, LLC
HSBC Securities (USA) Inc.
c/o J.P. Morgan Securities Inc.
277 Park Avenue
New York, New York 10172

November 9, 2006

VIA EDGAR AND FACSIMILE

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Song P. Brandon, Esq.

Re:		Emergent BioSolutions Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-136622

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join with the Company to request acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-136622), as amended (the “Registration Statement”), so that it may become effective at 5:00 p.m. Eastern time on November 14, 2006, or as soon thereafter as practicable.

In connection with Rule 460 under the Act, please be advised that, during the period from October 30, 2006 to the date of this letter, we have effected approximately the following distribution of copies of the Preliminary Prospectus dated October 30, 2006:

		No. of Copies
Prospective Underwriters			5,762
Institutions			500
Total			6,262

The undersigned has and will, and each participating underwriter and dealer has advised the undersigned that it has and will, comply with the provisions of SEC Release No. 33-4968 of the Act and Rule 15c2-8 of the Securities Exchange Act of 1934, as amended, in connection with the above referenced issue.

Very truly yours,

For itself and on behalf of the
several Underwriters